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We previously described the use of extended polymerase chain reaction (PCR) to amplify contiguous 9.2-kilobase (kb)
single-long terminal repeat (LTR) proviral sequences from HIV-1 genetic subtypes A through G. We now extend these findings
by describing a novel vector system to recover infectious molecular clones from long PCR amplicons. Directional ligation of
9.2-kb proviral amplicons into a recovery vector reconstitutes missing LTR sequences, providing candidate molecular clones
for infectivity screening. We show that a previously characterized infectious molecular clone of HIV-1 retains its biological
properties upon recovery with this strategy. Three additional infectious molecular clones generated, from primary isolates
of subtype B (HIV-1WR27) and circulating recombinant form 01_AE (subtype E) (HIV-1CM235) by subtype-specific LTR reconsti-
tution, displayed biological properties reflecting their cognate parental isolates. This represents the first report of infectious
molecular clones from circulating recombinant form 01_AE (subtype E). © 2000 Academic PressINTRODUCTION
Infectious molecular clones of the human immunode-
ficiency virus type 1 (HIV-1) have been critical tools in the
dissection of the basic mechanisms of viral replication
and pathogenesis as well as in the extraordinary genetic
diversity of HIV-1. They have permitted a systematic eval-
uation of the biological and immunological characteris-
tics of HIV-1 genes and will be useful in the development
of preventive vaccines, as they provide a functional con-
text for viral gene products.
Infectious molecular clones are difficult to recover,
given the high proportion of defective viral genomes
produced during HIV-1 infection (Li et al., 1991, 1992;
Meyerhans et al., 1989). Currently available infectious
molecular clones have been derived from subtype B
strains, either from chronically infected neoplastic T-cell
lines or from late-staged patients. These reagents fail to
reflect prevalent virus in the pandemic. Early techniques
to recover infectious molecular clones of HIV-1 involved
genomic library construction in bacteriophage l to re-
cover integrated or circularly permuted, nonintegrated
proviral forms that could subsequently be restored to
infectious form through ligation. Although feasible, these
1 To whom correspondence and reprint requests should be ad-
ressed at Walter Reed Army Institute of Research, Division of Retro-
irology, 1600 E. Gude Drive, Rockville, MD 20850. Fax: (301) 424-2923.
-mail: nmichael@hivresearch.org.
103approaches were both laborious and inefficient. The ad-
vent of the polymerase chain reaction (PCR) and discov-
ery of thermal stable DNA polymerases (Saiki et al., 1985,
1988) allowed for the amplification of multiple, 4- to
5-kilobase (kb), subgenomic proviral sequences that
could be reconstituted into full-length proviruses (Gibbs
et al., 1994). This approach, however, was highly suscep-
tible to the production of mosaic proviral genomes.
The addition of thermal stable DNA polymerases with
39 to 59 exonucleotidyl repair activities and modified salt
conditions allowed for the amplification of very long DNA
targets (Barnes, 1994; Cheng et al., 1994). Terminally
redundant LTR sequences in HIV-1 prohibit PCR-medi-
ated recovery of complete proviral genomes. Thus, our
previously described approach to recover virtually full-
length HIV-1 proviral sequences as a single, contiguous
9.2-kb DNA fragment from all known genotypes (Salmi-
nen et al., 1995b) yielded proviral amplicons with incom-
plete LTR sequences. Although this provided a powerful
tool for the study of global HIV-1 subtype evolution and
recombination (Carr et al., 1996; Salminen et al., 1995a,
1996), the amplified proviruses were not recovered in an
infectious form. We now describe a system affording the
recovery of infectious molecular clones of primary iso-
lates of HIV-1 from subtype B and circulating recombi-
nant form (CRF)01_AE (subtype E) (Robertson et al., 2000)
by reconstitution of the missing LTR sequences, in which
the biological properties of these reagents reflect those
of their cognate parental isolates.
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104 SALMINEN ET AL.RESULTS
nfectious molecular clone recovery strategy
We developed a combined PCR amplification and mo-
ecular cloning vector strategy, which allows for the am-
lification and direct cloning of HIV-1 proviral sequences
o produce an infectious molecular clone. Virtually full-
ength provirus is amplified as a single, contiguous
.2-kb DNA fragment, beginning at the junction of the 59
TR and gag leader sequence and extending to the R/U5
egion junction of the 39 LTR. Primers used for the am-
lification generate the restriction enzyme recognition
equences for BbeI and BglI at the 59 and 39 ends,
espectively, of the fragment. Both sites are otherwise
bsent from the genomes of all previously described
ull-length HIV-1 proviruses. Because of the absence of
TR sequences, the amplicon is incapable of producing
nfectious virus upon transfection into susceptible cells.
e developed vectors to replace the missing LTR se-
uences from both subtype B and CRF01_AE (subtype E)
IV-1 (pLTR(B)1/2D, and pLTR(E)1/2D, respectively (Fig.
). pLTR(B)1/2D and pLTR(E)1/2D contain LTR sequences
rom the infectious molecular clone pNL4-3 and the iso-
ate HIV-1CM235, respectively (see Material and Methods).
Upon BbeI, BglI directional cloning of the proviral ampli-
con into these vectors, the genomic organization of the
entire provirus is precisely regenerated and is potentially
infectious.
Recovery of infectious molecular clones
To test the validity of the strategy, we amplified and
FIG. 1. Plasmid map of LTR replacement vectors pLTR(B)1/2D and
LTR(E)1/2D. The cloning vector pBC KS1 was modified to contain 59
nd 39 LTR sequences which, upon ligation of 9.2-kb proviral fragments
erived from long PCR with unique 59 terminal BbeI and 39 terminal BglI
restriction sites, reconstitutes a complete provirus and infectious mo-
lecular clone candidate (pIMC). LTR sequences were derived from
HIV-1NL4-3 and HIV-1CM235 for vectors pLTR(B)1/2D and pLTR(E)1/2D,
respectively.cloned proviral sequences from the reference subtype B
infectious molecular pNL4-3, initially derived from bacte-
c
nriophage l library screening. We also recovered proviral
sequences from HIV-1WR27, a subtype B R5X4 isolate, and
HIV-1CM235, a CRF01_AE (subtype E) R5 isolate, to test
hether the method could be used to generate infectious
olecular clones from primary viruses. HIV-1CM235 was
chosen, as this strain is representative of HIV-1 prevalent
in Thailand (Carr et al., 1996), where large-scale, preven-
tive vaccine efficacy trials are planned. We were able to
generate infectious molecular clones from the reference
clone and both of the primary isolates. Virtually full-
length HIV-1WR27 and HIV-1CM235 proviruses were ligated
nto pLTR(B)1/2D and pLTR(E)1/2D, respectively, to pro-
ide subtype-specific LTR reconstitution.
During the recovery of infectious clones from HIV-
WR27, 48 of 6 3 10
3 bacterial colonies were positive upon
initial hybridization screening, 26 of these contained full-
length proviral inserts, and 11 of 15 clones tested pro-
duced p24 antigen following transfection into COS-1
cells. Only one of these 11 stocks (pWR27-1) was capa-
ble of infecting PHA/IL-2-stimulated, seronegative donor
peripheral blood mononuclear cells (PBMC). Two molec-
ular clones derived from HIV-1CM235, capable of spreading
infection in PBMC, were also obtained in this fashion
(with similarly low stepwise yields) and were designated
pCM235-2 and pCM235-4. Complete genome sequenc-
ing of the three infectious molecular clones derived from
primary isolates revealed an absence of gross deletions,
nonsense mutations, or evidence for genetic rearrange-
ment.
Attempts to recover an infectious molecular clone of
HIV-1WR27 from a bacteriophage l library resulted in a
single molecular clone that failed to propagate in sub-
sequent PBMC infections.
Biological characterization of infectious molecular
clones
We compared the biological properties of the original
pNL4-3 bacteriophage l-derived infectious molecular
clone with its cognate reamplified and restored pL-
TR(B)1/2D-derived clone. The biological properties of the
primary isolate WR27 were compared to those of the
pWR27–1 infectious molecular clone produced by PCR.
To compare viral replication kinetics, we transfected mo-
lecular clones into COS-1 cells to produce initial inocu-
lum viral stocks, and then used these to infect PHA/IL-
2-stimulated PBMC to generate short-term passage viral
stocks. A PBMC stock was similarly prepared from the
HIV-1WR27 isolate. All viral stocks were titered on PBMC
erived from the same donor leukopack. Figure 2 shows
he results of p24 antigen production from PBMC in-
ected with 100 TCID50 of each virus stock. As shown in
ig. 2a, comparison of the parental HIV-1NL4-3 bacterio-
phage l-derived virus and the PCR-generated infectious
lone derived from it revealed equivalent replication ki-
etics. The MT-2 cell-derived biological phenotype and
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PBMC background in a different experiment than for the cognate
clones. All other parental isolates were tested at the same time as their p
105HIV-1 INFECTIOUS MOLECULAR CLONEScoreceptor utilization profiles were also maintained (Ta-
ble 1).
There was no appreciable difference between the
PBMC replication kinetics of either the parental HIV-1WR27
isolate or the cognate infectious molecular clone
pWR27–1 (Fig. 2b). pWR27–1 also retained the SI pheno-
type of the parental isolate and exclusively utilized
CXCR4; the parental HIV-1WR27 isolate predominately uti-
lized CXCR4, indicating that a representative clone was
recovered from the quasi-species (Table 1). Both
pCM235-2 and pCM235-4 replicated equivalently in
PBMC compared with parental HIV-1CM235 (Fig. 2c), were
NSI, and exclusively used CCR5 (Table 1).
We next examined the replication kinetics of the infec-
tious molecular clones in primary human macrophages.
As expected, both the parental and PCR-derived HIV-
1NL4-3 infectious molecular clones failed to replicate in
acrophages (Table 1). Minimal replication in macro-
hages (peak p24 antigen level , 1000 pg/ml) was
bserved for both HIV-1WR27 and pWR27-1 (Table 1). Both
pCM235-2 and pCM235-4, despite being NSI and show-
ing exclusive CCR5 utilization, failed to replicate in pri-
mary macrophages, as was previously noted by our
group for HIV-1CM235 (J. R. Mascola, unpublished obser-
ations). The observations are consistent with recent
ata showing that biological phenotype and coreceptor
tilization assays imperfectly predict efficient replication
n primary macrophages (Cheng-Mayer et al., 1997;
hesebro et al., 1996; Dittmar et al., 1997; Smyth et al.,
998) and that envelope-dependent, postentry activation
f primary macrophages may influence tropism (Arthos
t al., 2000).
The MT-2 phenotype, coreceptor preference, and mac-
ophage replication kinetics of five control viruses, HIV-
MN, HIV-1BaL, HIV-1JR-FL, HIV-1JR-CSF, and HIV-1ADA-M, were
onsonant with their predicted properties. HIV-1MN was
SI phenotype, exclusively used CXCR4, and failed to
replicate in primary macrophages, while the remaining
four viruses were NSI, exclusively used CCR5, and were
capable of macrophage replication (Table 1).
DISCUSSION
Molecular virologic and phylogenetic studies of full-
length HIV-1 genomes have largely been conducted us-
ing infectious molecular clones derived from screening
of bacteriophage l libraries. We now show that an alter-
ative approach, using PCR amplification of virtually full-
ength proviruses followed by molecular cloning into an
TR reconstitution vector, can generate infectious molec-
cognate clones. Representative data from one of three iterations of
these experiments are shown. (a) HIV-1NL4-3 and pNL4-3-1 PCR stocks.FIG. 2. Replication kinetics of infectious molecular clones in periph-
eral blood mononuclear cells. One hundred TCID50 of PBMC viral
stocks were used to infect three separate groups of PHA/IL-2-stimu-
lated PBMC. Virus replication was monitored by mixing equal aliquots
of culture supernatant fluid from each of the three infections followed
by singleton p24 antigen concentration testing of the pooled superna-
tants. p24 antigen concentration is given on a log10 y-axis for each plot.
iral stocks from PCR-derived infectious molecular clones are given in
losed squares or diamonds and parental isolates in open squares.
he HIV-1CM235 isolate replication kinetics were obtained on the same(b) HIV-1WR27 and pWR27-1 stocks. (c) HIV-1CM235, pCM235-2, and
CM235-4 stocks.
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106 SALMINEN ET AL.ular clones of HIV-1 from primary isolates, which reflect
the biological properties of the parental isolate.
This cloning strategy initially results in heterologous 59
LTR and 39 U5 sequences. Following initial transfection
nd reinfection, however, all but 31 bp of the distal R and
he complete 83-bp U5 region are replaced by autolo-
ous LTR sequences during reverse transcription. These
eterologous sequences could be replaced with autolo-
ous sequences by standard molecular biological tech-
iques, when critical to an experimental design. Al-
hough the primers used in the provirus amplification
ere previously found to amplify subtypes A through G
Salminen et al., 1995b), the LTR reconstitution vectors
described here were optimized for subtypes B and E
proviruses. During reverse transcription, strong-stop
DNA containing R, U5, and primer binding site se-
quences with minus-strand orientation jump to the 39
LTR, where efficient hybridization between strong-stop
and viral RNA 39 R region sequences must occur. R
region incompatibilities in an inter-subtype RNA–DNA
heteroduplex could interfere with efficient viral replica-
tion. Preliminary data in our laboratory suggest that this
does occur when attempting to recover PCR amplicons
of HIV-1 CRF01_AE (subtype E) into pLTR(B)1/2D (sub-
type B) (unpublished data). However, generation of pL-
TR(B/E)1/2D analogs from different subtypes should per-
mit the efficient recovery of infectious molecular clones
from any HIV-1 subtype.
The future applications of the approach described
here are myriad. We are in the process of developing a
panel of infectious molecular clones from all described
HIV-1 subtypes for the delineation of subtype-specific
T
Viral Phenotype and Coreceptor Prefe
Virus stockb Subtype
MT-2
phenotypec
pNL4-3 B SI
pNL4-3-1 SI
WR27 B SI
pWR27-1 SI
pCM235-2 AE NSI
pCM235-4 NSI
MN B SI
BaL B NSI
JR-FL B NSI
JR-CSF B NSI
ADA-M B NSI
a Co-receptor utilization is given as the percentage of total usage fo
b pNL4-3 stock was derived from the original bacteriophage lambda
PCR and LTR reconstruction. Remaining stocks are isolates.
c Viral phenotype as assessed by the presence or absence of syncy
d Expressed as peak p24 antigen expression in acute infections ofreplication kinetics, transcriptional regulation, corecep-
tor utilization, and inter-subtype recombination events.
W
dThese infectious molecular clones will provide a stan-
dardized panel of reagents both to develop novel vaccine
immunogens and to test host cellular immune responses
to them in preclinical and clinical trials. An infectious
molecular clone of HIV-1 subtype D was recently recov-
ered in our laboratory, confirmed by whole-genome se-
quencing, and is now being biologically characterized
(data not shown).
Finally, the availability of completely characterized,
quality-controlled, permanent seed stocks of HIV-1 vi-
ruses of different subtypes will provide an essential,
long-term resource for all aspects of HIV diagnostics,
therapy, and prevention. Such a panel is readily attain-
able based on the results reported herein.
MATERIALS AND METHODS
HIV-1 parental molecular clones and isolates
HIV-1 infectious molecular clone pNL4-3 was obtained
from the NIAID AIDS Research and Reference Reagent
Program. The plasmid was propagated in E. coli strain
DH5a and purified for transfection and PCR experiments
using Qiagen columns (Qiagen, Chatsworth, CA). pNL4-3
is an infectious molecular clone of the T-cell-line-
adapted virus HIV-1NL4-3, which uses the coreceptor
XCR4 and induces syncytia (syncytium-inducing, SI
henotype) in MT-2 cells (Adachi et al., 1986). HIV-1NL4-3
belongs to HIV-1 group M, subtype B, and its biological
properties were previously characterized (Adachi et al.,
1986). HIV-1 subtype B isolate WR27 (HIV-1WR27) was
btained in 1988 by short-term coculture of peripheral
lood mononuclear cells (PBMC) from a subject with
for Experimental and Control Viruses
acrophage replicationd
(pg/ml p24 antigen)
Co-receptor utilizationa
CCR5 CXCR4
,15 0.0 100.0
,15 0.0 100.0
376 5.6 94.4
112 0.0 100.0
,15 100.0 0.0
,15 100.0 0.0
,15 0.0 100.0
.1,250,000 100.0 0.0
419,838 100.0 0.0
209,701 100.0 0.0
.1,250,000 100.0 0.0
d X4.
hile pNL4-3-1, pCM235-2, and pCM235-4 stocks were derived by long
ation in MT-2 cells.
macrophage cultures.ABLE 1
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clone walter Reed Stage 5, symptomatic HIV-1 infection as
escribed previously (Salminen et al., 1995b) and HIV-1
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107HIV-1 INFECTIOUS MOLECULAR CLONESCRF01_AE (subtype E) isolate CM235 (HIV-1CM235) was
btained from an early-stage HIV-1-infected individual in
orthern Thailand (McCutchan et al., 1992).
olymerase chain reaction
Virtually complete provirus was amplified from DNA
xtracted at the peak of p24 antigen production from
nfected PBMC or from the original infectious molecular
lone in the case of pNL4-3. Primers MSF12 (AAA-
CTCTAGCAGTGGCGCCCGAACAG) and MSR5 (ACGT-
GCcCTCAAGGCAAGCTTTATTGAGGCT) were used to
amplify the provirus as previously described (Salminen
et al., 1995b). Note that primer MSR5 was modified from
MSR5 (Salminen et al., 1995b) to include a 4-bp 59-clamp
sequence followed by A to C mutation at position 7
(lowercase) to generate a BglI restriction enzyme site
(underlined). Primer MSF12 contains a natural BbeI/NarI
site (underlined). Both sites are GC rich and do not occur
at other positions in the HIV-1 genome among all de-
scribed complete HIV-1 genomes.
Preparation of vector plasmid backbone
Construction of the LTR reconstitution vectors pL-
TR(B)1/2D and pLTR(E)1/2D was based on the 3.4-kb
lasmid pBC KS1 (Stratagene, La Jolla, CA), which car-
ies the chloramphenicol acetyl transferase (CAT) gene
s well as a polylinker sequence. A unique BglI site in
pBC KS1 was removed by digestion with restriction
nzymes NaeI and PvuI, followed by blunting and religa-
ion of the ends. The resulting plasmid was digested with
baI and EcoRI and linear forms were recovered by gel
urification.
reparation of LTR-cloning cassette
LTR sequences of HIV-1 were PCR amplified from the
nfectious molecular clone pNL4-3 or from genomic DNA
solated from PBMC infected with HIV-1CM235. The LTR-cas-
sette assembly strategy was the same for both NL4-3 and
CM235. Primer sequences and restriction sites differ, to
reflect template sequence differences. For NL4-3 a 661-bp
complete 59-LTR (LTR1, Fig. 1) was amplified using primers
MSF13 (GGCTAGTCTAGATGGAAGGGCTAATTTGGTC-
CCAAA) and MSR7 (GCATGCGGATCCGTTCGGGCGCCACT-
GCTAGAGATT); the 116-bp 39-U5 region (LTR2D) was
amplified using primers MSF15 (GCATGCGGATCCGCCTT-
GAGgGCTACAAGTAGTGTG) and MSR8 (GCATGCGAATTC-
CTGCTAGAGATTTTCCACACTGA). These primers contained
restriction enzyme recognition sites XbaI, BamHI, BamHI,
and EcoRI, respectively (underlined). For CM235 cognate
PCR fragments of 670 and 122 bp (Fig. 1) were amplified
using primers E-f13 (GCATGCCCTAGGTGGAWGGGC-
TARTTYACTCCAAGA) and E-r7 (GCATGCGGATCCGT-
TCGGGCGCCACTGCTAGAGATT); and E-f15 (GCATGC-
GGATCCGCCTTGAGgGCTTAAAGTGGTGTG) and E-r8
(GCATGCGAATTCCTGCTAGAGATTTTTACTCAGT), re-
o
aspectively. These primers contained restriction en-
zyme recognition sites AvrII, BamHI, BamHI, and
EcoRI, respectively (underlined). MSF15 and E-f15
primer sequences reflect a one-base transversion
(T 3 G, lowercase), which introduces a unique BglI
restriction enzyme recognition site at the junction be-
tween the R and U5 regions. MSR7 and E-r7 each
contain a natural BbeI site (boldface).
The amplified LTR fragments were cloned into vector
pCR-II (Invitrogen, San Diego, CA) and sequenced using
a Model 377 DNA sequencer (Applied Biosystems, Fos-
ter City, CA). NL4-3 LTR1 and LTR2D clones that agreed
with the published LTR sequences from pNL4-3 (Gen-
Bank accession number M19921) were selected and
double-digested with XbaI plus BamHI, and BamHI plus
coRI restriction enzyme combinations, respectively, to
elease the LTR fragments. Sequences from HIV-1CM235
LTR clones were found to be virtually identical to those
from the highly related strain HIV-1CM240 (GenBank acces-
ion number U54771). Individual clones of HIV-1CM235 59
TR sequences were selected, based on their ability to
upport basal and Tat-enhanced transcription using pre-
iously described assays (Michael et al., 1994). CM235
TR1 and LTR2D clones were derived from those en-
bling the best transcription and double-digested with
vrII plus BamHI, and BamHI plus EcoRI, respectively.
omologous digested LTR products were gel purified
nd ligated at the BamHI site to join the two LTR frag-
ents in a cassette containing one 59-LTR1 and one
9-LTR2D. Fragments of the correct size were gel purified
nd ligated to the previously prepared pBC-KS1 XbaI
lus EcoRI-digested plasmid backbone, and the trans-
ormants were screened for the proper insert. The AvrII
nd XbaI sites are ligation compatible with resultant loss
f both sites. The final constructions, pLTR(B)1/2D and
LTR(E)1/2D derived from HIV-1NL4-3 and HIV-1CM235, re-
pectively, were confirmed by DNA sequencing. Thus,
IV-1 provirus amplified with primers MSF12 and MSR5
an be directionally inserted into these vectors by means
f the unique restriction enzyme sites BglI and BbeI (or
arI) to regenerate potentially infectious molecular
lones of HIV-1.
olecular cloning of full-length HIV-1 provirus
To directly clone amplified HIV-1 provirus into the
LTR(B)1/2D and pLTR(E)1/2D vectors, MSF12/MSR5-
mplified PCR products were pooled, extracted with phe-
ol:chloroform:isoamyl alcohol (25:24:1), ethanol precip-
tated, and resuspended in sterile, deionized water. A
-mg sample of the fragment was first digested in BbeI
uffer with 5 to 10 units of BbeI (Panvera, Madison, WI)
or 5 to 8 h at 37°C in a total volume of 10 ml. Next, 0.7 ml
f 103 concentrated BglI reaction buffer and 5 to 10 units
f BglI (New England Biolabs, Beverly, MA) were added
nd the fragment was digested overnight at 37°C in a
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108 SALMINEN ET AL.total volume of 12 ml. pLTR(B)1/2D and pLTR(E)1/2D were
digested with BbeI and BglI in a similar fashion. The
igestion products were organic-extracted, gel purified
ith the QiaQuick technique (Qiagen), ligated together,
lectroporated into E. coli DH5a cells, and recovered on
uria–Bertani medium (LB) plates containing 20 mg/ml of
hloramphenicol (Sigma, St. Louis, MO) at 32°C. Trans-
ormants were picked into individual wells of sterile 96-
ell plates containing 200 ml of LB supplemented with 20
mg/ml of chloramphenicol, grown overnight at 32°C, and
replica plated onto 137-mm-diameter nitrocellulose fil-
ters (Protran; Schleicher & Schuell, Keene, NH) overlying
150-mm-diameter LB-chloramphenicol plates. After over-
night growth at 32°C, the filters were denatured, neutral-
ized, washed, and UV-crosslinked as previously de-
scribed (Artenstein et al., 1995). Dried filters were
screened for correct inserts using a [32P] random primer-
labeled probe (NL4-3 9.2-kb fragment bounded by
MSF12/MSR5). Bacteria from positive wells were
streaked out onto fresh LB-chloramphenicol plates and
the resulting colonies were screened for the proper vec-
tor and insert sequences by restriction enzyme diges-
tion.
Bacteriophage l cloning
Seronegative donor PBMC, depleted of CD81 cells by
adherence to a flask coated with a CD8 monoclonal
antibody (MicroCELLector; Applied Immune Sciences,
Santa Clara, CA), were acutely infected with a cell-free
stock of the primary isolate WR27. Cells were harvested
at the peak of p24 antigen production and high-molecu-
lar-weight DNA was prepared by spooling. Following
partial digestion with Sau3A to generate an average
insert size of 15-kb pairs, a genomic library was prepared
in Lambda Fix-it II (Stratagene) and 2 3 106 plaques
were screened with a full-length HIV probe.
Recovery of viral stocks
Samples of LTR-reconstituted proviral clones (20–25
mg) were transfected into 1.5 3 107 COS-1 cells by
lectroporation (0.22 kV, 960 mF). The COS-1 cells were
hen maintained in a humidified, 5% CO2 environment at
7°C for 48 h posttransfection in DMEM supplemented
ith 10% fetal calf serum (PAA Laboratories, Newport
each, CA), 100 U/ml penicillin, 100 mg/ml streptomycin,
nd 2 mM L-glutamine. Supernatants were saved and 3
l of fresh medium was added to each well for an
dditional 24 h. At 72 h posttransfection supernatant
luids were then cleared by centrifugation at 300 g, fil-
ered through 0.22-mM syringe filters (Millipore, Bedford,
A), and monitored for p24 antigen production by the
oulter assay (Coulter, Hialeah, FL). p24 antigen-positive
upernatants, typically in the 0.3 to $20 ng/ml range,
ere subsequently tested for infectivity.eripheral blood mononuclear cell growth kinetics
PHA/IL-2-stimulated seronegative donor PBMC (2 3
06) were exposed to 1 ml of p24 antigen-positive COS-1
ell supernatant. After overnight infection, cells were
ashed and maintained in culture media (RPMI 1640
upplemented with 15% fetal calf serum, 100 U/ml peni-
illin, 100 mg/ml streptomycin, and 2 mM L-glutamine)
containing 20 U/ml human recombinant IL-2. Virus repli-
cation was monitored by p24 antigen production and
culture supernatant harvested at peak p24 antigen pro-
duction was used to measure virus tissue culture infec-
tious dose 50 (TCID50). To measure virus growth kinetics,
riplicate wells of a 96-well microtiter plate, containing
.5 3 105 PHA/IL-2-stimulated PBMC per well, were in-
ected overnight with ;100 TCID50 of each virus stock.
ells were washed and maintained in IL-2-supple-
ented culture media. One-half of the culture superna-
ant was harvested and replaced every 2 to 3 days for 20
ays. Culture supernatant from triplicate wells was
ooled and p24 antigen was measured in batch at the
nd of the assay.
acrophage replication kinetics
Macrophages were prepared from PBMC of HIV-1 se-
onegative donors by overnight adherence to plastic
lasks precoated with heat-inactivated normal human
erum (NHS). Nonadherent cells were removed by vig-
rous washing with culture media and macrophages
ere detached using cold Ca21- and Mg21-free phos-
hate-buffered saline (PBS) as described (Gartner et al.,
986). Macrophages were then seeded at 1 3 105 cells
er well in flat-bottomed 96-well microtiter plates and
aintained in culture media supplemented with 10%
HS for 7 days prior to infection. To evaluate virus
rowth kinetics, cells in triplicate wells were exposed
vernight to ;400 TCID50 of virus stock and washed
thoroughly, and culture supernatant p24 antigen was
monitored every 3 to 4 days for 4 weeks. Culture super-
natant from triplicate wells was pooled and p24 antigen
was measured in batch at the end of the assay. Control
macrophage-tropic (BaL, JR-CSF, JR-FL, ADA-M) and T-
cell-line-adapted viruses (MN) were obtained from the
NIAID AIDS Research and Reference Reagent Program
and propagated in PHA/IL-2-stimulated PBMC.
MT-2 phenotyping assay
The ability of the PBMC-derived viruses to induce
syncytia in MT-2 cells was evaluated using the AIDS
Clinical Trials Group consensus protocol (Japour et al.,
1994). MT-2 cells were exposed to 200 TCID50 of each
virus in duplicate wells. Viruses were assigned the SI
phenotype if $three syncytia per low-powered field
(1003) were observed during a 21-day observation pe-
riod.
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Coreceptor usage was evaluated using human osteo-
blastic sarcoma (HOS) cells transduced with CD4, CD4
plus CCR5, or CD4 plus CXCR4 as previously described
(Michael et al., 1997) for all viruses except HIV-1CM235,
here typing was done using a modification of the
HOST cell assay (Michael et al., 1998). The percentage
GFP-positive cells in mock-infected GHOST cells was
subtracted from that of viral-infected GHOST cells. The
percentage GFP-positive infected parental cells was
then subtracted from that of all other receptor-trans-
duced GHOST cell infections to control for low-level,
endogenous CXCR4 expression. Finally, these corrected
percentages of GFP-positive cells were normalized for
relative cell line GFP production, reflected by parallel
infections with MLV-E pseudotyped HIV-1 (which enter
GHOST cells independently of CD4 or coreceptor utiliza-
tion), by multiplication by the ratio (mean GHOST MLV-E
percentage GFP positives/coreceptor specific MLV-E
percentage GFP positives).
Full-length proviral sequencing
Infectious molecular clones of HIV-1NL4-3, HIV-1WR27,
IV-1CM235-2, and HIV-1CM235-4 were sequenced on a Model
377 Applied Biosystems automated sequencer; contigs
representing complete sequencing on both strands were
assembled using Sequencher version 3.1 software (Gene
Codes Corporation, Ann Arbor, MI); and consensus se-
quences were submitted to GenBank for each. HIV-1NL4-3
and HIV-1WR27 are deposited with accession numbers
U26942 and AF286365, respectively; HIV-1CM235-2 and HIV-
CM235-4 were deposited with accession numbers
AF259954 and AF259955, respectively. New sequences
were compared to reference sequences using the
MegAlign program contained within the DNAStar pack-
age (DNAStar, Madison, WI).
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